This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology

Treatment Trials

Focus your search

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

Description

Conditions